Sobre nervocure
Sobre nervocure
Blog Article
Patients remain at the heart of the work at Novocure, guiding us forward in our goal to deliver a novel, safe and efficacious cancer therapy that prolongs survival while maintaining patient quality of life.
Se interessou? Entãeste corra de modo a garantir este seu NervoCure no sitio oficial do fabricante. Lá você encontra descontos especiais e a garantia do estar adquirindo um produto original e de capacidade.
Design changes in the second generation device using improved electronic components, circuit boards and digital signaling technology, resulted in reduced weight and increased operational efficiency for people with glioblastoma multiforme, improving the patient experience with TTFields treatment. (Top left, 1st generation Optune; Top Right, 2nd generation Optune; Bottom panels, patients wearing 2nd generation Optune with white and tan arrays).
Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfields.utilizando.
Precise placement of the transducer arrays is important to optimize the clinical effect of TTFields. Novocure has developed the NovoTAL software system to optimize array layouts based on individual patient head size, tumour location and magnetic resonance imaging data for the specific characteristics of the patient’s tumour9. Preclinical studies show that the effects of TTFields increase with intensity, which underscores the critical need to understand how TTFields intensities distribute within the tumour region. There are pelo practical means for measuring field intensities within the brain tissue and tumours of patients undergoing treatment.
Your browser isn’t supported anymore. Update it to get the best YouTube experience and our latest features. Learn more
investor relations home stock information corporate presentation SEC filings press releases corporate governance
Continuar comprando Finalizar compra Ir de modo a o carrinho Não foi possível adicionar este Resultado ao carrinho
The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.
A melhor parte é de que muitas pessoas relatam sentir ESTES pontos positivos do NervoCure em menos de um mês do uso regular.
Simulations and modelling are the nervocure primary tools for obtaining these essential data (Fig. 4). Simulation-based studies using realistic head models have shown that TTFields effectively penetrate the brain and tumour tissue. The field distribution is heterogeneous and depends on the anatomy of the individual patient, the physical properties of the various tissue types and the location of the tumour10. The position of arrays can therefore be optimized using the NovoTAL System to deliver maximal field intensities to the tumour region of the individual patient10,11.
About Novocure Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma.
Ongoing research suggests that TTFields may also inhibit DNA damage repair, impair cellular migration and invasion4 and upregulate autophagy5. The resulting daughter cells exhibit various forms of cell death including immunogenic cell death, suggesting that combining TTFields with immunotherapies may enhance the body’s own antitumour immunity6.